The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for ...

The contest, which aims to accelerate the development of recombinant protein-based oncology therapies, will culminate at CPHI ...

Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 ...

PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, ahead of BIO 2025 to find out ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Elkedonia will develop first-in-class Elk1 inhibitors for treatment-resistant depression, targeting neuroplasticity without ...

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.

Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving ...

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs ...